Healthcare entity
Source depth averages 2.3 original sources per story, versus 6.4 across the same-window beat baseline. The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. Of the tracked stories, 1 of 3 also mention AstraZeneca Plc, the most common co-covered peer.
Last mentioned: 2h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Source depth averages 2.3 original sources per story, versus 6.4 across the same-window beat baseline. The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. Of the tracked stories, 1 of 3 also mention AstraZeneca Plc, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 6.3 for that window. That works out to roughly 1 story per week across a 22-day span. We currently track 3 Healthcare stories that mention Morgan Stanley, published between June 19, 2026 and July 10, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 74 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Morgan Stanley. Shared-story counts are live from our verified record — not editorial picks.
Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Six major institutional investors have collectively added over 3.8 million AstraZeneca shares across recent quarters, signaling strong professional confidence in the company's diversified healthcare portfolio spanning oncology, cardiovascular, respiratory, and rare disease treatments. The sustained buying pattern highlights institutional conviction in AstraZeneca's ability to deliver innovative therapies that address critical unmet medical needs.
Source: Ticker Report · Watch List News
Morgan Stanley’s upgrade of Charles River and downgrade of IQVIA signal a shift in healthcare R&D outsourcing. CROs with deep ties to small biotech stands to gain as venture funding rebounds, potentially accelerating drug development timelines and altering cost structures for health systems.
Morgan Stanley is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
